Literature DB >> 19164198

Treatment of growing teratoma syndrome.

David J Vaughn, Keith Flaherty, Priti Lal, Maryann Gallagher, Peter O'Dwyer, Keith Wilner, Isan Chen, Gary Schwartz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19164198     DOI： 10.1056/NEJMc0808558

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  26 in total

1.  Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy.

Authors:  Patrick J Roberts; John E Bisi; Jay C Strum; Austin J Combest; David B Darr; Jerry E Usary; William C Zamboni; Kwok-Kin Wong; Charles M Perou; Norman E Sharpless
Journal:  J Natl Cancer Inst       Date:  2012-02-01       Impact factor: 13.506

2.  Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts.

Authors:  Karine Michaud; David A Solomon; Eric Oermann; Jung-Sik Kim; Wei-Zhu Zhong; Michael D Prados; Tomoko Ozawa; C David James; Todd Waldman
Journal:  Cancer Res       Date:  2010-03-30       Impact factor: 12.701

Review 3.  The history and future of targeting cyclin-dependent kinases in cancer therapy.

Authors:  Uzma Asghar; Agnieszka K Witkiewicz; Nicholas C Turner; Erik S Knudsen
Journal:  Nat Rev Drug Discov       Date:  2015-02       Impact factor: 84.694

4.  Mitigation of hematologic radiation toxicity in mice through pharmacological quiescence induced by CDK4/6 inhibition.

Authors:  Søren M Johnson; Chad D Torrice; Jessica F Bell; Kimberly B Monahan; Qi Jiang; Yong Wang; Matthew R Ramsey; Jian Jin; Kwok-Kin Wong; Lishan Su; Daohong Zhou; Norman E Sharpless
Journal:  J Clin Invest       Date:  2010-06-23       Impact factor: 14.808

5.  Cytoplasmic p21 expression levels determine cisplatin resistance in human testicular cancer.

Authors:  Roelof Koster; Alessandra di Pietro; Hetty Timmer-Bosscha; Johan H Gibcus; Anke van den Berg; Albert J Suurmeijer; Rainer Bischoff; Jourik A Gietema; Steven de Jong
Journal:  J Clin Invest       Date:  2010-09-01       Impact factor: 14.808

6.  Targeting the RB-pathway in cancer therapy.

Authors:  Erik S Knudsen; Jean Y J Wang
Journal:  Clin Cancer Res       Date:  2010-02-09       Impact factor: 12.531

Review 7.  Platinum-refractory germ cell tumors: an update on current treatment options and developments.

Authors:  Christoph Oing; Winfried H Alsdorf; Gunhild von Amsberg; Karin Oechsle; Carsten Bokemeyer
Journal:  World J Urol       Date:  2016-07-23       Impact factor: 4.226

8.  MLL fusion-driven activation of CDK6 potentiates proliferation in MLL-rearranged infant ALL.

Authors:  Marieke H van der Linden; Merel Willekes; Eddy van Roon; Lidija Seslija; Pauline Schneider; Rob Pieters; Ronald W Stam
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

Review 9.  Molecular Mechanisms of Cisplatin Chemoresistance and Its Circumventing in Testicular Germ Cell Tumors.

Authors:  Silvia Schmidtova; Katarina Kalavska; Lucia Kucerova
Journal:  Curr Oncol Rep       Date:  2018-09-26       Impact factor: 5.075

Review 10.  Emerging Therapeutic Targets for Male Germ Cell Tumors.

Authors:  Christian Daniel Fankhauser; Friedemann Honecker; Jörg Beyer; Peter Karl Bode
Journal:  Curr Oncol Rep       Date:  2015-12       Impact factor: 5.075
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.